Artiva Biotherapeutics (NASDAQ:ARTV) versus CG Oncology (NASDAQ:CGON) Financial Comparison

CG Oncology (NASDAQ:CGON) and Artiva Biotherapeutics (NASDAQ:ARTV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares CG Oncology and Artiva Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
Artiva Biotherapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares CG Oncology and Artiva Biotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$200,000.00	11,652.65	-$48.61 million	N/A	N/A
Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Artiva Biotherapeutics has lower revenue, but higher earnings than CG Oncology.

Analyst Recommendations

This is a summary of recent ratings and target prices for CG Oncology and Artiva Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0	0	8	1	3.11
Artiva Biotherapeutics	0	0	5	0	3.00

CG Oncology presently has a consensus price target of $63.88, indicating a potential upside of 85.36%. Artiva Biotherapeutics has a consensus price target of $21.25, indicating a potential upside of 63.84%. Given CG Oncology’s stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Artiva Biotherapeutics.

Insider & Institutional Ownership

26.6% of CG Oncology shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

CG Oncology beats Artiva Biotherapeutics on 6 of the 9 factors compared between the two stocks.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.